LAKE BLUFF, Ill.--(BUSINESS WIRE)--NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has reached a settlement agreement with Diosynth, RTP (“Diosynth”). As previously noted, NeoPharm reported that it had entered into various contractual arrangements with Diosynth to secure access to manufacturing capacity for the potential manufacture and regulatory advancement of Cintredekin Besudotox through early 2008.
